AuraVax Therapeutics Inc. ("AuraVax") is a privately held biotechnology company developing a proprietary and differentiated platform of vaccines and therapeutics. Its lead candidate is an intranasal vaccine for COVID-19. The next-generation platform aims to combine the ease of use of "at-home" administration with the ability to deliver comprehensive immunity for use in humans and animals. The technology has been validated for COVID-19 in pre-clinical studies with immunity measured by both B-cell and T-cell responses.
